Insulin Glargine Management in Insulin-Naïve Adults
Start insulin glargine at 10 units once daily OR 0.1-0.2 units/kg/day, administered subcutaneously at the same time each day, and titrate by increasing 2 units every 3 days until fasting plasma glucose reaches 5.5 mmol/L (100 mg/dL) without hypoglycemia. 1
Starting Dose
The 2025 ADA Standards of Care provide clear guidance 1:
- 10 units per day as a flat dose, OR
- 0.1-0.2 units/kg per day for weight-based dosing
This represents the most current guideline recommendation and applies to both insulin glargine 100 U/mL and 300 U/mL formulations.
Titration Schedule
Use an evidence-based prophylactic titration algorithm 1:
Every 3 days, adjust the dose based on fasting plasma glucose:
- FPG <4.4 mmol/L (<79 mg/dL): Decrease by 2 units
- FPG 4.4-7.0 mmol/L (79-126 mg/dL): No change
- FPG 7.1-10.0 mmol/L (127-180 mg/dL): Increase by 2 units
- FPG >10.0 mmol/L (>180 mg/dL): Increase by 4 units
Alternative patient-managed approach: Increase by 2 units every 3 days if FPG remains above target, provided no blood glucose <4.0 mmol/L (<72 mg/dL) 2. Research comparing three algorithms found that simpler titration schedules (like the 2-unit every-3-days approach) achieved similar glycemic control with lower hypoglycemia rates than more aggressive weekly algorithms 3.
Target fasting plasma glucose: 5.5 mmol/L (100 mg/dL) to achieve HbA1c <7% 1, 2
Administration Technique
- Route: Subcutaneous injection only 4
- Timing: Once daily at the same time each day (typically bedtime or morning)
- Sites: Rotate injection sites within the same region (abdomen, thigh, or deltoid) to reduce lipodystrophy risk
- Never share: Insulin pens, syringes, or needles between patients due to bloodborne pathogen transmission risk 4
The once-daily dosing is a key advantage over NPH insulin, which requires twice-daily administration 5, 6.
Contraindications
Per FDA labeling 4:
- Hypersensitivity to insulin glargine or any excipients
- During episodes of hypoglycemia
Monitoring Requirements
At Every Visit:
Assess for signs of overbasalization 1:
- Elevated bedtime-to-morning glucose differential
- Elevated postprandial-to-preprandial glucose differential
- Hypoglycemia (aware or unaware)
- High glucose variability
These signals indicate the need for adjunctive therapies (GLP-1 RA or prandial insulin) rather than further basal insulin increases.
Ongoing Monitoring:
- Fasting plasma glucose: Daily during titration, then as needed once stable
- HbA1c: Every 3-6 months 1
- Hypoglycemia awareness: At each visit, with dose reduction of 10-20% if hypoglycemia occurs without clear cause 1
- Weight: Monitor for typical 3 kg gain over 6 months 7
- Potassium levels: Insulin causes hypokalemia; monitor in at-risk patients 4
Critical Pitfalls to Avoid
Overbasalization: Approximately 50% of patients achieve HbA1c ≤7% with basal insulin doses around 40-70 units/day 7. If A1C remains above goal despite adequate fasting glucose control, add GLP-1 RA or prandial insulin rather than continuing to increase basal insulin 1.
Medication errors: Insulin glargine must never be diluted or mixed with other insulins, as this alters its pharmacokinetic profile 4. The acidic pH formulation precipitates in neutral subcutaneous tissue, creating the depot effect that provides 24-hour coverage 5, 6.
Hypoglycemia management: If hypoglycemia occurs, determine the cause first. If no clear reason exists (missed meal, unusual exercise, medication error), reduce the dose by 10-20% 1. Prescribe glucagon for emergency use 1.
Fluid retention: When combining with thiazolidinediones (PPAR-gamma agonists), monitor for heart failure symptoms 4.
Special Considerations
For patients already on GLP-1 receptor agonists, consider fixed-ratio combination products (iGlarLixi) for simplified regimens 1. The newer insulin glargine 300 U/mL formulation provides >24-hour duration with more stable glucose-lowering and lower nocturnal hypoglycemia risk compared to glargine 100 U/mL, though both are effective 8.
Patient-managed titration (with nurse support) achieves non-inferior results to physician-managed titration with similarly low hypoglycemia rates, making it a viable option for motivated patients 9.